New York is home to several companies who are building the next wave of gene therapies, bringing the hope of curative, "one and done" interventions for a wide range of conditions. This panel will feature CEOs from New York companies, including Alexandria Forbes, President and CEO of MeiraGTx and Nolan Townsend, CEO of Lexeo Therapeutics and will be moderated by Michael Glynn of Fox Rothschild. We will discuss the near and long-term hurdles and the future promise of these modalities, which have the potential to be truly disruptive breakthroughs in therapy across several indications.

This panel is sponsored by Fox Rothschild.